Newsroom

Download PDF Cambridge, MA, July 22, 2008 – Dyax Corp. (NASDAQ: DYAX) and AVEO Pharmaceuticals, Inc. announced today that Dyax has granted AVEO a non-exclusive license to Dyax’s proprietary antibody phage display libraries for the discovery and development of therapeutic antibodies.  Dyax’s human antibody phage libraries combine gene fragments from human donors with strategically designed

Download PDF CAMBRIDGE, Mass., May 29, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that they have completed enrollment in their 200-patient Phase 2 clinical trial of AV-951 in patients with metastatic renal cell carcinoma (mRCC).  “We are very

Download PDF – Novel Technology Has Identified Multiple Targets Yielding Rich Pipeline of High-Value Oncology Antibodies – CAMBRIDGE, Mass., May 22, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that on May 13, 2008, the United States Patent and

Download PDF CAMBRIDGE, MA, May 15, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 2008 Citi Investment Research Global Health Care Conference on Thursday, May 22, 2008 at 11:00 a.m. (ET) at the Hilton New York in New York City. About AVEO

Download PDF CAMBRIDGE, MA, May 2, 2008 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Leerink Swann Solid Tumors Roundtable Conference on Friday, May 9, 2008 at 10:20 a.m. (ET) at the Grand Hyatt in New York City. In addition, Murray Robinson, Ph.D.,

Download PDF Proprietary Human Response Platform Data Reveal Distinct Biomarkers PotentiallyCritical to Determining Treatment Success    SAN DIEGO, Calif and CAMBRIDGE, Mass, April 14, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that their novel oral triple VEGF receptor inhibitor

Download PDF Six Abstracts on AVEO’s Proprietary Human Response Platform Also to be PresentedCAMBRIDGE, Mass., April 8, 2008 — AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that it will present a total of six oral and poster presentations at the

Download PDF CAMBRIDGE, MA, March 20, 2008 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the Future Leaders in the Biotech Industry Conference on Thursday, March 27, 2008 at 2:00 p.m. (ET) at the Millennium Broadway Hotel in New York City. About AVEO AVEO is a